POPE is a multinational, multicentre, prospective, observational, non-interventional registry of patients with chronic obstructive pulmonary disease (COPD) in Central and Eastern Europe. The aim of the POPE study is to assess the distribution of patients with COPD in clinical practice within the CEE region according to disease severity, disease category, and phenotypes. The study was initiated as the pilot cooperation of COPD PLATFORM in the CEE region and 11 countries from Central and Eastern Europe have been involved in the project.

About COPD and POPE-Study

Chronic Obstructive Pulmonary Disease (COPD) is a significant cause of morbidity and mortality in Europe and a major consumer of resources in both primary and secondary healthcare. Both clinical features of disease severity and quality of COPD patient care may have substantial influence on disease outcomes. Traditionally, COPD has been categorized using the FEV1-based GOLD (2011) classification.

Other factors independently associated with survival include age, dyspnoea, health status, lung hyperinflation, gas exchange abnormalities, exacerbation frequency, exercise capacity, pulmonary haemodynamic, and nutritional status. Together these factors explain some of the existent heterogeneity within each GOLD stage in terms of symptoms, exacerbations, quality of life and exercise capacity.

The most frequently reported phenotypes are emphysema and chronic bronchitis, along with a subset of asthma sufferers. Recently, an extended list of proposed phenotypes have been proposed (6) including: (A) infrequent exacerbators with either chronic bronchitis or emphysema; (B) overlap COPD-asthma; (C) frequent exacerbators with emphysema predominant; and (D) frequent exacerbators with chronic bronchitis predominant. While there is consensus of substantial, but not complete, overlap among these phenotypes, the distribution of these phenotypes may differ widely between different countries and healthcare systems.

The objectives of this study are to better understand the patient characteristics and treatment patterns of those diag­nosed with COPD between different CEE countries. Knowledge of this information may provide insight into the variability of phenotypes between different healthcare systems and may subsequently contribute to a better understanding of the factors associated with patient outcomes and have the potential to improve the care of COPD patients.